LeMaitre Q2 2024 Financial Results

Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) reported strong Q2 2024 financial results, with sales reaching $55.8 million, up 11% (12% organic) year-over-year. The company saw significant growth in key product lines and regions, with allografts up 30%, bovine patches up 12%, and carotid shunts up 22%. Geographically, APAC sales increased 20%, EMEA 13%, and the Americas 10%.

Notably, gross margin improved to 68.9%, a 490 basis point increase from Q2 2023, driven by manufacturing efficiencies and higher average selling prices. Operating income surged 52% to $14.4 million, with net income up 46% to $11.8 million. The company announced a quarterly dividend of $0.16 per share and provided an optimistic outlook for Q3 and full-year 2024, projecting continued sales and profit growth.

Positive

• Sales increased 11% (12% organic) to $55.8 million in Q2 2024
• Gross margin improved significantly to 68.9%, up 490 basis points year-over-year
• Operating income surged 52% to $14.4 million
• Net income increased 46% to $11.8 million
• Earnings per diluted share grew 44% to $0.52
• Cash position improved by $4.8 million sequentially to $113.1 million
• Strong growth in key product lines: allografts (+30%), bovine patches (+12%), and carotid shunts (+22%)
• Robust regional performance: APAC sales up 20%, EMEA up 13%, Americas up 10%
• Increased full-year 2024 guidance, projecting 13% sales growth and 39% operating income growth
• Board approved a quarterly dividend of $0.16 per share

Negative

• Operating expenses grew 6% year-over-year

Financial Analyst

LeMaitre's Q2 2024 results demonstrate robust financial performance and operational efficiency. The 11% year-over-year sales growth to $55.8 million, coupled with a substantial 490 basis point improvement in gross margin to 68.9%, signals strong market demand and effective cost management. The 52% increase in operating income to $14.4 million is particularly impressive, reflecting the company's ability to scale operations efficiently.

Key growth drivers include allografts (+30%), bovine patches (+12%) and carotid shunts (+22%), indicating a diversified product portfolio. The geographic sales growth, led by APAC at 20%, suggests successful market penetration strategies.

The company's financial outlook is optimistic, with full-year 2024 guidance projecting sales of $216.8 million to $220.8 million, representing a 13% growth at the midpoint. The projected operating margin improvement to 23% for 2024 from 19% in 2023 indicates ongoing operational efficiencies.

LeMaitre's strong cash position of $113.1 million and the newly authorized $50 million share repurchase program provide financial flexibility for future growth initiatives or potential acquisitions. The consistent quarterly dividend of $0.16 per share further underscores the company's commitment to shareholder returns.

Overall, LeMaitre's Q2 2024 results and forward-looking guidance paint a picture of a company with solid fundamentals and growth potential in the vascular devices market.

Medical Research Analyst

LeMaitre's Q2 2024 results reveal significant growth in key product segments, particularly in allografts, bovine patches and carotid shunts. This growth pattern suggests an increasing adoption of these products in vascular surgeries and procedures.

The 30% growth in allografts is particularly noteworthy. Allografts, which are tissue grafts from human donors, are increasingly preferred in vascular surgeries due to their biocompatibility and reduced risk of rejection. This substantial growth could indicate a shift in surgical preferences or an expansion of LeMaitre's market share in this segment.

The 12% growth in bovine patches also merits attention. These patches, derived from bovine pericardium, are widely used in vascular reconstruction procedures. Their continued growth suggests sustained demand in procedures such as carotid endarterectomy and peripheral artery disease treatments.

The 22% increase in carotid shunts sales is indicative of a potential rise in carotid endarterectomy procedures. This could be attributed to an aging population or improved diagnostic capabilities leading to earlier interventions in carotid artery disease.

The company's strong performance across diverse product lines suggests a well-rounded portfolio catering to various vascular surgery needs. This diversification not only mitigates risk but also positions LeMaitre to capitalize on evolving trends in vascular medicine.

Looking ahead, the projected 13% organic growth for 2024 implies continued market expansion and product adoption. This growth trajectory, if sustained, could potentially accelerate research and development efforts, leading to further innovations in vascular devices and implants.

BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance.

Q2 2024 Financial Results

• Sales $55.8mm, +11% (+12% organic) vs. Q2 2023  
• Gross margin 68.9%, +490 bps
• Op. income $14.4mm, +52%
• Op. margin 26%
• Net income $11.8mm, +46%
• Earnings per diluted share $0.52, +44%
• Cash up $4.8mm sequentially to $113.1mm

Allografts (+30%), bovine patches (+12%) and carotid shunts (+22%) led Q2 sales growth. APAC sales increased 20%, EMEA 13% and the Americas 10%.

The gross margin increased to 68.9% (vs. 64.0% in Q2 2023), driven by manufacturing efficiencies and higher average selling prices.

Operating income of $14.4mm was up 52% vs. Q2 2023. Operating expenses grew 6% year-over-year due to restrained headcount growth and reduced regulatory spending. 144 sales reps were on staff at quarter end.

Chairman/CEO George LeMaitre said, “2024 is shaping up to be another year of healthy sales and profit growth. Increased guidance now implies a 23% op. margin in 2024, vs. 19% in 2023.”

Business Outlook

	Q3 2024 Guidance	Full Year 2024 Guidance
Sales	$52.7mm - $54.7mm (Mid: $53.7mm, +13%, +14% Org.)	$216.8mm - $220.8mm (Mid: $218.8mm, +13%, + 13% Org.)
Gross Margin	68.0%	68.4%
Op. Income	$11.3mm - $12.7mm (Mid: $12.0mm, +31%)	$49.7mm - $52.5mm (Mid $51.1mm, +39%) (Mid: $51.1mm, +37% Ex-Special)*
Op. Margin (Mid)	22%	23%
EPS	$0.42 - $0.46 (Mid: $0.44, +32%)	$1.82 - $1.91 (Mid: $1.86, +39%) (Mid: $1.86, +37% Ex-Special)*

*Special charges in 2023 were related to the St. Etienne factory closure.

Quarterly Dividend

On July 25, 2024, the Company's Board of Directors approved a quarterly dividend of $0.16/share of common stock. The dividend will be paid on August 29, 2024, to shareholders of record on August 15, 2024.

Share Repurchase Program

On February 21, 2024, the Company's Board of Directors authorized the repurchase of up to $50.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 21, 2025, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events, including EBITDA. This press release also provides guidance for operating income and EPS excluding the special charge relating to the closure of our St. Etienne factory and revenue related to the Aziyo distribution agreement. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and the aforementioned non-GAAP profitability measures to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that the presentation of guidance described above for sales, operating income and EPS provides an alternative and meaningful view of the Company’s profitability.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, companies that develop products or services that may impact the use of our products such as drugs to treat diabetes or weight loss; the risks from competition from other companies; the status of our global regulatory approvals and compliance with regulatory requirements to market and sell our products both in the U.S. and outside of the U.S.; risks related to product demand and market acceptance of the Company’s products and pricing; risks from implementing a new enterprise resource planning system; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that we may not be able to maintain our recent levels of profitability; our reliance on sole source suppliers; disruptions or breaches of information technology systems; the risk that the Company may not realize the anticipated benefits of its strategic activities; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the acceleration or deceleration of product growth rates; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
			June 30, 2024				December 31, 2023
			(unaudited)
Assets
Current assets:
	Cash and cash equivalents		$	22,268			$	24,269
	Short-term marketable securities			90,831				80,805
	Accounts receivable, net			30,822				25,064
	Inventory and other deferred costs			63,673				58,080
	Prepaid expenses and other current assets			5,217				6,380
Total current assets				212,811				194,598
Property and equipment, net				23,117				21,754
Right-of-use leased assets				17,294				18,027
Goodwill				65,945				65,945
Other intangibles, net				38,767				41,711
Deferred tax assets				1,028				1,003
Other assets				4,117				3,740
Total assets			$	363,079			$	346,778
Liabilities and stockholders' equity
Current liabilities:
	Accounts payable		$	1,995			$	3,734
	Accrued expenses			20,785				23,650
	Acquisition-related obligations			75				24
	Lease liabilities - short-term			2,591				2,471
Total current liabilities				25,446				29,879
Lease liabilities - long-term				15,818				16,624
Deferred tax liabilities				104				107
Other long-term liabilities				2,179				2,268
Total liabilities				43,547				48,878
Stockholders' equity
	Common stock			240				239
	Additional paid-in capital			208,689				200,755
	Retained earnings			129,961				115,430
	Accumulated other comprehensive loss			(5,094	)			(4,625	)
	Treasury stock			(14,264	)			(13,899	)
Total stockholders' equity				319,532				297,900
Total liabilities and stockholders' equity			$	363,079			$	346,778

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
		For the three months ended							For the six months ended
		June 30, 2024				June 30, 2023			June 30, 2024				June 30, 2023
Net sales		$	55,849			$	50,115		$	109,327			$	97,190
Cost of sales			17,381				18,029			34,194				34,221
Gross profit			38,468				32,086			75,133				62,969
Operating expenses:
	Sales and marketing		10,984				10,216			22,670				21,113
	General and administrative		8,820				7,722			17,833				15,654
	Research and development		4,284				4,516			8,376				8,391
	Restructuring		-				180			-				485
Total operating expenses			24,088				22,634			48,879				45,643
Income from operations			14,380				9,452			26,254				17,326
Other income (expense):
	Interest income		1,137				682			2,138				1,250
	Foreign currency gain (loss)		(11	)			185			(89	)			(240	)
Income before income taxes			15,506				10,319			28,303				18,336
Provision for income taxes			3,680				2,221			6,590				4,198
Net income		$	11,826			$	8,098		$	21,713			$	14,138
Earnings per share of common stock
	Basic	$	0.53			$	0.36		$	0.97			$	0.64
	Diluted	$	0.52			$	0.36		$	0.96			$	0.63
Weighted - average shares outstanding:
	Basic		22,458				22,213			22,412				22,162
	Diluted		22,725				22,451			22,657				22,371
Cash dividends declared per common share		$	0.16			$	0.14		$	0.32			$	0.28

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
		For the three months ended												For the six months ended
		June 30, 2024						June 30, 2023						June 30, 2024						June 30, 2023
		$			%			$			%			$			%			$			%
Net Sales by Geography
	Americas	$	36,907		66	%		$	33,507		67	%		$	72,152		66	%		$	65,633		67	%
	Europe, Middle East and Africa		15,298		27	%			13,580		27	%			29,693		27	%			25,857		27	%
	Asia Pacific		3,644		7	%			3,028		6	%			7,482		7	%			5,700		6	%
Total Net Sales		$	55,849		100	%		$	50,115		100	%		$	109,327		100	%		$	97,190		100	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
				For the three months ended								For the six months ended
				June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
Reconciliation between GAAP and Non-GAAP EBITDA
	Net income as reported			$	11,826			$	8,098			$	21,713			$	14,138
	Interest income				(1,137	)			(682	)			(2,138	)			(1,250	)
	Amortization and depreciation expense				2,384				2,326				4,766				4,677
	Provision for income taxes				3,680				2,221				6,590				4,198
	EBITDA			$	16,753			$	11,963			$	30,931			$	21,763
	EBITDA percentage increase								40	%							42	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Reconciliation between GAAP and Non-GAAP sales growth:
	For the three months ended June 30, 2024
		Net sales as reported		$	55,849
		Net distribution sales (non-organic)			(348	)
		Impact of currency exchange rate fluctuations			394
		Adjusted net sales						$	55,895
	For the three months ended June 30, 2023
		Net sales as reported		$	50,115
		Adjusted net sales						$	50,115
		Adjusted net sales increase for the three months ended June 30, 2024						$	5,780		12%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the three months ending September 30, 2024
		Net sales per guidance (midpoint)		$	53,710
		Impact of currency exchange rate fluctuations			238
		Adjusted projected net sales						$	53,948
	For the three months ended September 30, 2023
		Net sales as reported		$	47,411
		Adjusted net sales						$	47,411
		Adjusted projected net sales increase for the three months ending September 30, 2024						$	6,537		14%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the year ending December 31, 2024
		Net sales per guidance (midpoint)		$	218,847
		Net distribution sales (non-organic)			(1,612	)
		Impact of currency exchange rate fluctuations			450
		Adjusted projected net sales						$	217,685
	For the year ended December 31, 2023
		Net sales as reported		$	193,484
		Adjusted net sales						$	193,484
		Adjusted projected net sales increase for the year ending December 31, 2024						$	24,201		13%
Reconciliation between GAAP and Non-GAAP projected operating income:
	For the year ending December 31, 2024
		Operating income per guidance (midpoint)		$	51,096
		Adjusted projected operating income						$	51,096
	For the year ended December 31, 2023
		Operating income as reported		$	36,712
		Impact of special charge			485
		Adjusted operating income						$	37,197
		Adjusted projected operating income increase for the year ending December 31, 2024						$	13,899		37%
Reconciliation between GAAP and Non-GAAP projected EPS:
	For the year ending December 31, 2024
		EPS per guidance (midpoint)		$	1.86
		Adjusted EPS						$	1.86
	For the year ended December 31, 2023
		EPS as reported		$	1.34
		Impact of special charge			0.02
		Adjusted EPS						$	1.36
		Adjusted projected EPS increase for the year ending December 31, 2024						$	0.50		37%

FAQ

What were LeMaitre's (LMAT) Q2 2024 sales figures?

LeMaitre (LMAT) reported Q2 2024 sales of $55.8 million, representing an 11% increase (12% organic) compared to Q2 2023.

How did LeMaitre's (LMAT) gross margin perform in Q2 2024?

LeMaitre's (LMAT) gross margin in Q2 2024 improved to 68.9%, an increase of 490 basis points compared to 64.0% in Q2 2023.

What is LeMaitre's (LMAT) earnings per share (EPS) for Q2 2024?

LeMaitre (LMAT) reported earnings per diluted share of $0.52 for Q2 2024, a 44% increase compared to the same period last year.

What is LeMaitre's (LMAT) dividend for Q2 2024?

LeMaitre (LMAT) announced a quarterly dividend of $0.16 per share, payable on August 29, 2024, to shareholders of record on August 15, 2024.

What is LeMaitre's (LMAT) full-year 2024 sales guidance?

LeMaitre (LMAT) provided full-year 2024 sales guidance of $216.8 million to $220.8 million, with a midpoint of $218.8 million, representing a 13% increase year-over-year.